Company intelligence / Profile preview

Cyncado Therapeutics

Westport, Connecticut, United Statescyncado.com ↗
Ownership
Private
Development stage
Other
01

Overview

Cyncado is advancing clinical programs to achieve proof-of-concept data for its adenosine receptor antagonists. The company is focusing on dual administration of A2a and A2b antagonists to overcome immune suppression in the tumor microenvironment[3][4].

Therapeutic areas
Oncology
Modalities
Small molecules
Industry
Biotech
02

Drug pipeline

1 asset

PORT-9

Discontinued

Beyond the preview

Go deeper on Cyncado Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyncado Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call